Cargando…

Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells

The development of acquired EGFR‐TKI therapeutic resistance is still a serious clinical problem in the management of lung adenocarcinoma. Peroxisome proliferator activated receptor gamma (PPAR γ) agonists may exhibit anti‐tumor activity by transactivating genes which are closely associated with cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ni, Jie, Zhou, Lei‐lei, Ding, Li, Zhang, Xue‐qin, Zhao, Xia, Li, Huizi, Cao, Haixia, Liu, Siwen, Wang, Zhuo, Ma, Rong, Wu, Jianzhong, Feng, Jifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943475/ https://www.ncbi.nlm.nih.gov/pubmed/29573196 http://dx.doi.org/10.1002/cam4.1440

Ejemplares similares

Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment
por: Cao, Haixia, et al.
Publicado: (2016)

Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro
por: Lou, Rui, et al.
Publicado: (2019)

Overexpression of KIF20A confers malignant phenotype of lung adenocarcinoma by promoting cell proliferation and inhibiting apoptosis
por: Zhao, Xia, et al.
Publicado: (2018)

Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro
por: Hu, Yong, et al.
Publicado: (2017)

MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5-fluorouracil in MEK1 Q56P-mutant colorectal cancer cells
por: Jing, Changwen, et al.
Publicado: (2019)

Hemistepsin A inhibits T0901317-induced lipogenesis in the liver
por: Kim, Jae Kwang, et al.
Publicado: (2021)

Long noncoding RNA and mRNA profiling in cetuximab‐resistant colorectal cancer cells by RNA sequencing analysis
por: Jing, Changwen, et al.
Publicado: (2019)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells
por: Rough, James J, et al.
Publicado: (2010)

Combination of Gefitinib and DNA Methylation Inhibitor Decitabine Exerts Synergistic Anti-Cancer Activity in Colon Cancer Cells
por: Lou, Yun-feng, et al.
Publicado: (2014)

Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma
por: Yang, Hong, et al.
Publicado: (2021)

Long noncoding RNAs predict the survival of patients with colorectal cancer as revealed by constructing an endogenous RNA network using bioinformation analysis
por: Zhang, Hui, et al.
Publicado: (2019)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

In Vitro and in Vivo Efficacy of NBDHEX on Gefitinib-resistant Human Non-small Cell Lung Cancer
por: Sha, Huanhuan, et al.
Publicado: (2020)

Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
por: Stoppoloni, Daniela, et al.
Publicado: (2010)

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
por: Hu, Yong, et al.
Publicado: (2017)

Combination therapy with gefitinib and doxorubicin inhibits tumor growth in transgenic mice with adrenal neuroblastoma
por: Kawano, Kumi, et al.
Publicado: (2013)

Sputum cell‐free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR‐TKIs
por: Wang, Zheng, et al.
Publicado: (2021)

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer
por: Zou, Zheng-Zhi, et al.
Publicado: (2015)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis
por: Liu, Yun, et al.
Publicado: (2015)

Cancer-associated changes of emotional brain network in non-nervous system metastatic non-small cell lung cancer patients: a structural connectomic diffusion tensor imaging study
por: Liu, Siwen, et al.
Publicado: (2020)

Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma
por: WANG, ZHUN, et al.
Publicado: (2015)

Nedaplatin reduces multidrug resistance of non-small cell lung cancer by downregulating the expression of long non-coding RNA MVIH
por: Jing, Changwen, et al.
Publicado: (2020)

A Liver-X-Receptor Ligand, T0901317, Attenuates IgE Production and Airway Remodeling in Chronic Asthma Model of Mice
por: Shi, Ying, et al.
Publicado: (2014)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Lentivirus‐mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro
por: Li, Ya‐Qing, et al.
Publicado: (2017)

Screening key lncRNAs for human rectal adenocarcinoma based on lncRNA‐mRNA functional synergistic network
por: Zhu, Xiongwen, et al.
Publicado: (2019)

Ketamine induces apoptosis in lung adenocarcinoma cells by regulating the expression of CD69
por: Zhou, Xuhui, et al.
Publicado: (2018)

Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K/Akt pathway
por: Wang, Yingying, et al.
Publicado: (2021)

Serum Platelet-Derived Growth Factor Is Significantly Lower in Patients with Lung Cancer and Continued to Decrease After Platinum-Based Chemotherapy
por: Ma, Rong, et al.
Publicado: (2020)

Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer
por: Komatsu, Yoshito, et al.
Publicado: (2013)

LXR ligands induce apoptosis of EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt-NF-κB activation
por: Liu, Siwen, et al.
Publicado: (2018)

The somatic mutation landscape of Chinese Colorectal Cancer
por: Ma, Rong, et al.
Publicado: (2020)

Screening of immunosuppressive cells from colorectal adenocarcinoma and identification of prognostic markers
por: Li, Fazhan, et al.
Publicado: (2021)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Akt/mTOR and AMPK signaling pathways are responsible for liver X receptor agonist GW3965-enhanced gefitinib sensitivity in non-small cell lung cancer cell lines
por: Wang, Qingbo, et al.
Publicado: (2019)

Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels
por: Du, Jiali, et al.
Publicado: (2020)

miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
por: Ge, Peng, et al.
Publicado: (2019)

Tumor stemness and immune infiltration synergistically predict response of radiotherapy or immunotherapy and relapse in lung adenocarcinoma
por: Shi, Hongjie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mbauegqoprv97gkr522b5e4ll4